<DOC>
	<DOCNO>NCT00093145</DOCNO>
	<brief_summary>This trial treat patient advance breast cancer new anti-cancer medicine use combination two exist anti-cancer medication : Albumin-bound paclitaxel ( ABI-007 ) , Carboplatin Herceptin . Participants give combination therapy weekly basis may continue therapy long condition improve drug toxicity tolerate .</brief_summary>
	<brief_title>Study Albumin-bound Paclitaxel ( Abraxane ) Combination With Carboplatin Herceptin Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed adenocarcinoma breast Tumor show 3+ overexpression human epidermal growth factor receptor 2 ( HER2 ) /protooncogene immunohistochemistry assay , fluorescence situ hybridization ( FISH ) + Stage IV disease Measurable disease At least 3 week since prior cytotoxic chemotherapy At least 4 week since radiotherapy full recovery At least 4 week since major surgery full recovery Eastern Cooperative Oncology Group ( ECOG ) performance status 02 At least 18 year old Absolute neutrophil count ( ANC ) least 1.5 x 10^9 cells/L Platelets least 100 x 10^9 cells/L Hemoglobin least 9 g/dL Aspartame aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less 2.5X upper limit normal Alkaline Phosphatase le 1.5X upper limit normal Creatinine le 1.5 gm/dL Normal leave ventricular ejection fraction Negative pregnancy test Agree use method avoid pregnancy Informed Consent obtain Up one regimen prior neoadjuvant adjuvant chemotherapy allow . One year since Taxane Herceptin treatment . Cumulative lifetime dose doxorubicin great 360 mg/m^2 Concurrent immunotherapy hormonal therapy Parenchymal brain metastasis , present , must document clinically radiographically stable least 6 month treatment Serious intercurrent medical psychiatric illness , include serious active infection History congestive heart failure History malignancy within last 5 year could affect diagnosis assessment breast cancer Patients receive investigational drug within previous 3 week Patient currently enrol another clinical study receive investigational therapy Pregnant nursing woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>